ASPC 2018 Congress on CVD Prevention

 

ASPC 2018 Congress on CVD Prevention
Avatar

Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App and More - A Town Hall Series - Umprecedented Barriers to Medication Access : A Growing Body of Evidence

By ASPC 2018 Congress on CVD Prevention FEATURING Seth Baum
By ASPC 2018 Congress on CVD Prevention FEATURING Seth Baum
106 views
August 10, 2018
Comments 0
Login to view comments. Click here to Login

Featured Video

04:47
Novartis Cardiology

Examining MOA, Safety, and Efficacy Data for a Non-Statin Lipid-Lowe…

Featured Video

15:01
Lilly Diabetes

Discover the MOA of an Incretin Medication for T2D

SESSION 1
28:44

Preventive Cardiology Now and 5 Years From Now, a Strategic Vision

The American Society for Preventive Cardiology

S. Fazio

238 views
23:50

Keynote Address: Genetics in CVD Prevention: Insights and Opportunit…

ASPC 2018 Congress on CVD Prevention

S. Kathiresan

122 views
19:52

Charting New Territory – Inflammation as a CVD Target

ASPC 2018 Congress on CVD Prevention

C. Ballantyne

282 views
30:16

Session 1 Question and Answer Panel Discussion and Audience Response…

ASPC 2018 Congress on CVD Prevention

14 views
05:27

Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App an…

ASPC 2018 Congress on CVD Prevention

M. Shapiro

257 views
10:00

Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App an…

ASPC 2018 Congress on CVD Prevention

S. Baum

106 views
07:09

Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App an…

ASPC 2018 Congress on CVD Prevention

S. Baum

151 views
38:27

Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App an…

ASPC 2018 Congress on CVD Prevention

S. Baum

93 views